Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey 08544, United States.
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, Victoria 3052, Australia.
Mol Pharm. 2021 Apr 5;18(4):1666-1676. doi: 10.1021/acs.molpharmaceut.0c01132. Epub 2021 Mar 3.
The combination of Flash NanoPrecipitation and hydrophobic ion pairing (HIP) is a valuable approach for generating nanocarrier formulations of ionic water-soluble drugs with controllable release properties dictated by liquid crystalline structuring of the ion pairs. However, there are few examples of this in practice in the literature. This work aims to decipher the influence of the nature of the hydrophobic counterion used in HIP and its consequent impact on liquid crystalline structuring and drug release. The hypothesis of this study was that hydrophobic counterions with different head and tail groups used for FNP with HIP would give rise to different liquid crystalline structures, which in turn would result in different drug release behavior. A cationic, water-soluble antibiotic, polymixin B, was complexed with eight different hydrophobic counterions with varying head and tail groups and encapsulated into nanocarriers 100-400 nm in size prepared using FNP. Sixteen formulations were assessed for internal structure by synchrotron small-angle X-ray scattering, and drug release was measured in physiological conditions. The liquid crystalline phases formed depended on the counterion head group and tail geometry, drug:counterion charge ratio, and the ionic strength and pH of the release medium. Drug release occurred more rapidly when no liquid crystalline phases were present and more slowly when higher-ordered phases existed. Specific findings include that phosphonic acid counterions lead to the formation of lamellar structures that persisted at pH 2.0 but were not present at pH 7.3. In contrast, sulfonic acids lead to lamellar or hexagonal phases that persisted at both pH 7.3 and 2.0, while hydrophobic counterions without alkyl tails did not form internal structures. It was also clear that the lipophilicity of the counterion does not dictate drug release. These findings confirm that the liquid crystalline phase behavior of the drug:counterion complex dictates drug release and significantly improves our understanding of the types of controlled release formulations that are possible using FNP with HIP.
Flash 纳米沉淀(Flash NanoPrecipitation,FNP)与疏水离子对(Hydrophobic Ion Pairing,HIP)的结合是一种有价值的方法,可用于生成具有可控释放特性的纳米载体配方,这些特性由离子对的液晶结构决定。然而,文献中实际应用的例子很少。这项工作旨在阐明在 HIP 中使用的疏水分子抗衡离子的性质及其对液晶结构和药物释放的影响。本研究的假设是,用于 FNP 与 HIP 的具有不同头部和尾部基团的疏水分子抗衡离子会产生不同的液晶结构,从而导致不同的药物释放行为。一种阳离子、水溶性抗生素多粘菌素 B 与具有不同头部和尾部基团的八种不同疏水分子抗衡离子复合,并包裹在使用 FNP 制备的 100-400nm 大小的纳米载体中。通过同步加速器小角 X 射线散射对内部分子结构进行了评估,并在生理条件下测量了药物释放。形成的液晶相取决于抗衡离子的头基和尾几何形状、药物与抗衡离子的电荷比以及释放介质的离子强度和 pH 值。当不存在液晶相时,药物释放更快,当存在更高阶相时,药物释放更慢。具体发现包括,膦酸抗衡离子导致层状结构的形成,该结构在 pH 2.0 时仍然存在,但在 pH 7.3 时不存在。相比之下,磺酸导致层状或六方相的形成,在 pH 7.3 和 2.0 时都存在,而没有烷基尾部的疏水分子抗衡离子则没有形成内部结构。显然,抗衡离子的亲脂性并不决定药物释放。这些发现证实了药物与抗衡离子复合物的液晶相行为决定了药物释放,并显著提高了我们对使用 FNP 与 HIP 可能实现的控释制剂类型的理解。